Rallybio 2026: Revenue $0 Net income ($2.73M), EPS ($0.48) — 10-Q Summary

Rallybio reported no revenue and a net loss of $2.73M in 2026, compared to $212K revenue and $16.02M net income in the prior year. The company agreed to merge with Avenzo, with investors providing $215M pre-merger. Rallybio also announced progress in its Phase 1 study of RLYB116.

Original reporting
Published Oct 27, 2026, 12:11 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 27, 2026, 12:17 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Rallybio 2026: Revenue $0 Net income ($2.73M), EPS ($0.48) — 10-Q Summary — source image
Decision brief

The 30-second read

$RLYBBearishLow
01

Why it matters

The earnings miss and merger news create short‑term downside risk, but the capital injection may support future R&D and a possible valuation boost if the transaction closes.

02

Market read

Micro‑cap biotech investors will weigh the earnings disappointment against the merger financing.

03

What to watch

Potential pre‑money valuation uplift from Avenzo investors and any upcoming clinical data releases.

Relevance 6/10Novelty 6/10Timing: post‑market today

Background

Rallybio is a clinical‑stage biotech that reported a quarterly loss and zero revenue while announcing a merger with Avenzo, which is providing significant cash support.

Company-level read

Ticker impact

$RLYBBearishMedium confidence
Context

Rallybio filed its 10‑Q showing zero revenue, a $2.73 M loss and a pending merger with Avenzo funded by $215 M.

Expected impact

likely downward pressure as the market prices in the earnings miss and merger uncertainty

Evidence & confidence

Earnings miss and no revenue are bearish for a micro‑cap; however, the $215 M cash infusion for the merger could mitigate downside if the deal closes.

Market effects

Highlights challenges for small biotech firms with no revenue and reliance on merger financing.

Limited to U.S. biotech micro‑cap segment.

Minimal; no broader market or macro impact.

Counterpoint

If the merger proceeds, the cash infusion could fund rapid development, offering upside beyond the earnings miss.

Key entities

  • Rallybio Corp

    Biotech issuer reporting the 10‑Q.

  • Avenzo

    Merger partner providing $215 M financing.

Related articles

$RLYBHigh

Rallybio Corporation announced today that, subject to the satisfaction or waiver of any outstanding closing conditions, it anticipates the transactions…

Rallybio Corp (RLYB) filed an SEC Form 8-K — Other Events. Item 8.01 Other Events. Rallybio Corporation (the “Company”) announced today that, subject to the satisfaction or waiver of any outstanding closing conditions, it anticipates the transactions contemplated by the Agreement and Plan of Merger and Reorganization (the “Merger Agreeme

$RLYBHighAI 8/10

The Rallybio Corporation, a Delaware corporation, entered into an Agreement and Plan of Merger and Reorganization with Avenzo Therapeutics, Inc., a Delaware…

Rallybio Corp (RLYB) filed an SEC Form 8-K — Other Events. Item 8.01 Other Events. As previously disclosed, on May 31, 2026, the Rallybio Corporation, a Delaware corporation (the “Company”), entered into an Agreement and Plan of Merger and Reorganization (the “Merger Agreement”) with Avenzo Therapeutics, Inc., a Delaware corporation (“Av